Unfortunately, this compound has a too low GLP-1R potency to offer a viable therapeutic solution
The associations were robust to using the weighted median and weighted mode (Additional file 2: Fig
Ozempics website notes that it "acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, the target for native GLP-1." The medication also lowers fasting blood glucose by stimulating insulin secretion, according to Ozempics website
The company plans to conduct dose optimization studies in the latter half of 2024, evaluating multiple doses of this formulation to guide registration-enabling studies
Several nanoparticle-based strategies have also been explored for siRNA delivery to the brain in AD treatment
Flagg EW, Coates RJ, Eley JW, Jones DP, Gunter EW, Byers TE et al